Status:
TERMINATED
Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Tumors
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.
Eligibility Criteria
Inclusion
- Documented diagnosis of malignant solid tumor with measurable disease
- Life expectancy of at least 12 weeks
- ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2
Exclusion
- Recent major surgery, radiation therapy or anti-cancer treatment
- History of any other prior malignancy within the last 5 years
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00195325
Start Date
August 1 2005
Last Update
March 26 2007
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Lexington, Kentucky, United States, 40536-0098
2
Cleveland, Ohio, United States, 44195
3
Nashville, Tennessee, United States, 37232-6307